PAK1 and squamous cell carcinoma: Notably, PAK1 inhibition via NVS‐PAK1‐1 demonstrates broad therapeutic promise, not only by attenuating aberrant signaling in cancer and neurodegeneration but also by enhancing immune responses, promoting epithelial differentiation in squamous cell carcinoma, and synergizing with chemotherapy to suppress tumor growth and metastasis in triple‐negative breast cancer.73, 74